The expiration of semaglutide’s patent in Brazil marks a relevant shift in the pharmaceutical landscape. After 20 years of exclusivity, other companies can now develop generic or similar versions, subject to regulatory approval.
Immediate impacts
- Increased market competition
- Potential price reduction
- Broader access to treatments
- New opportunities for pharmaceutical players
From an intellectual property perspective, this case highlights the strategic importance of patent lifecycle management.
What about Mounjaro?
Unlike semaglutide, tirzepatide (Mounjaro) remains under patent protection in Brazil.
- Filing date: June 2016
- Expected expiration: June 2036
Although there are discussions about compulsory licensing, the current situation suggests a low likelihood of an early compulsory patent license, given Brazil’s legal requirements.
Strategic perspective
The contrast between semaglutide and Mounjaro reinforces:
- The importance of patent monitoring
- The direct impact of IP on market dynamics
- Opportunities for post-patent market entry
Tavares IP supports companies in navigating Brazil’s patent landscape, identifying risks, timelines, and market opportunities.
Contact our team to strengthen your IP strategy in Brazil.
